Latest From BioView Ltd.
Device firms closed the final quarter of 2012 with $1.1 billion in financing, led by Volcano’s debt offering. Takeovers of Gambro and PSS Medical topped the device M&A list. At $196 million, Q4 diagnostic financing was the lowest quarter of the year, but IPOs returned with three public debuts. Amgen’s $415 million acquisition of deCODE was the largest diagnostic M&A.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Pharmaceuticals, and Medical Devices – and then categorized by type –Acquisition, Alliance, or Financing.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Diagnostic Imaging Equipment & Supplies
- Monitoring Equipment & Devices
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Middle East
- Parent & Subsidiaries
- BioView Ltd.
- Senior Management
Alan Schwebel , PhD, Pres. & CEO
Marina Wolfson, Dir., Fin.
- Contact Info
3 Pakris St. Rehovot
P.O. Box 4051 Nes Ziona , 70400
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.